Reply to Saeid Safiri and Erfan Ayubi's Letter to the Editor re: Nicholas J. Giacalone, William U. Shipley, Rebecca H. Clayman, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol 2017;71:952-60. Methodological Issues to Avoid Misinterpretation
- PMID: 28642020
- DOI: 10.1016/j.eururo.2017.06.007
Reply to Saeid Safiri and Erfan Ayubi's Letter to the Editor re: Nicholas J. Giacalone, William U. Shipley, Rebecca H. Clayman, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol 2017;71:952-60. Methodological Issues to Avoid Misinterpretation
Comment on
-
Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.Eur Urol. 2017 Jun;71(6):952-960. doi: 10.1016/j.eururo.2016.12.020. Epub 2017 Jan 9. Eur Urol. 2017. PMID: 28081860
-
Re: Nicholas J. Giacalone, William U. Shipley, Rebecca H. Clayman, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol 2017;71:952-60: Methodological Issues to Avoid Misinterpretation.Eur Urol. 2017 Sep;72(3):e63. doi: 10.1016/j.eururo.2017.06.008. Epub 2017 Jun 23. Eur Urol. 2017. PMID: 28648368 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
